These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 29315012)

  • 1. Development of an Anti-HER2 Monoclonal Antibody H2Mab-139 Against Colon Cancer.
    Kaneko MK; Yamada S; Itai S; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2018 Feb; 37(1):59-62. PubMed ID: 29315012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of H
    Yamada S; Itai S; Nakamura T; Chang YW; Harada H; Suzuki H; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Dec; 36(6):287-290. PubMed ID: 29172998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. H
    Itai S; Fujii Y; Kaneko MK; Yamada S; Nakamura T; Yanaka M; Saidoh N; Chang YW; Handa S; Takahashi M; Suzuki H; Harada H; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Aug; 36(4):143-148. PubMed ID: 28700270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H
    Kato Y; Ohishi T; Yamada S; Itai S; Takei J; Sano M; Nakamura T; Harada H; Kawada M; Kaneko MK
    Monoclon Antib Immunodiagn Immunother; 2019 Aug; 38(4):157-161. PubMed ID: 31199696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H
    Kato Y; Ohishi T; Takei J; Nakamura T; Sano M; Asano T; Sayama Y; Hosono H; Kawada M; Kaneko MK
    Monoclon Antib Immunodiagn Immunother; 2020 Aug; 39(4):123-128. PubMed ID: 32552424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Antihuman Epidermal Growth Factor Receptor 2 Monoclonal Antibody (H
    Kato Y; Ohishi T; Takei J; Nakamura T; Kawada M; Kaneko MK
    Monoclon Antib Immunodiagn Immunother; 2020 Aug; 39(4):135-139. PubMed ID: 32644843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Anti-HER2 Monoclonal Antibody H
    Tateyama N; Asano T; Ohishi T; Takei J; Hosono H; Nanamiya R; Tanaka T; Sano M; Saito M; Kawada M; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Aug; 40(4):184-190. PubMed ID: 34424760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. H
    Kato Y; Ohishi T; Sano M; Asano T; Sayama Y; Takei J; Kawada M; Kaneko MK
    Monoclon Antib Immunodiagn Immunother; 2020 Jun; 39(3):61-65. PubMed ID: 32423281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Novel Anti-HER2 Monoclonal Antibody H
    Takei J; Asano T; Tanaka T; Sano M; Hosono H; Nanamiya R; Tateyama N; Saito M; Suzuki H; Harada H; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Aug; 40(4):168-176. PubMed ID: 34424764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H
    Kaneko MK; Suzuki H; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2024 Apr; 43(2):35-43. PubMed ID: 38563783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H
    Takei J; Kaneko MK; Ohishi T; Kawada M; Harada H; Kato Y
    Exp Ther Med; 2020 Aug; 20(2):846-853. PubMed ID: 32765652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epitope Mapping of an Anti-HER2 Monoclonal Antibody (H
    Asano T; Takei J; Suzuki H; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Dec; 40(6):255-260. PubMed ID: 34958275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Cancer-Specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft Models.
    Kaneko MK; Suzuki H; Ohishi T; Nakamura T; Tanaka T; Kato Y
    Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defucosylated Monoclonal Antibody (H
    Suzuki H; Ohishi T; Nanamiya R; Kawada M; Kaneko MK; Kato Y
    Curr Issues Mol Biol; 2023 Sep; 45(10):7734-7748. PubMed ID: 37886932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locally misfolded HER2 expressed on cancer cells is a promising target for development of cancer-specific antibodies.
    Arimori T; Mihara E; Suzuki H; Ohishi T; Tanaka T; Kaneko MK; Takagi J; Kato Y
    Structure; 2024 May; 32(5):536-549.e5. PubMed ID: 38460519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of EMab-51, a Sensitive and Specific Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in Flow Cytometry, Western Blot, and Immunohistochemistry.
    Itai S; Kaneko MK; Fujii Y; Yamada S; Nakamura T; Yanaka M; Saidoh N; Handa S; Chang YW; Suzuki H; Harada H; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Oct; 36(5):214-219. PubMed ID: 28891752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of EMab-134, a Sensitive and Specific Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Detecting Squamous Cell Carcinoma Cells of the Oral Cavity.
    Itai S; Yamada S; Kaneko MK; Chang YW; Harada H; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Dec; 36(6):272-281. PubMed ID: 29090976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
    Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
    Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model.
    Matsui Y; Inomata M; Tojigamori M; Sonoda K; Shiraishi N; Kitano S
    Int J Oncol; 2005 Sep; 27(3):681-5. PubMed ID: 16077916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of novel murine monoclonal antibodies directed against the extracellular domain of human HER2 tyrosine kinase receptor.
    Kazemi T; Tahmasebi F; Bayat AA; Mohajer N; Khoshnoodi J; Jeddi-Tehrani M; Rabbani H; Shokri F
    Hybridoma (Larchmt); 2011 Aug; 30(4):347-53. PubMed ID: 21851234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.